Clinilabs and Ambulatory Monitoring. Inc., Form Strategic Alliance
Clinilabs has entered into a strategic alliance withAmbulatory Monitoring, Inc. (AMI), a medical device and service company.
AMI, located in Ardsley, NY, provides equipment for monitoring physiological functioning in ambulatory subjects. The company’s series of Motionlogger® Actigraphs are commercial devices for 24-hour monitoring of activity and sleep and have been validated through use in hundreds of studies in numerous clinical populations. AMI’s activity monitors can be applied in clinical trials of therapeutics for sleep, psychiatric, pain, hyperactivity, dermatologic (e.g., itch), and cardiovascular disorders, among others. AMI also providesthe original PVT-192 Psychomotor Vigilance Task Monitor.
The alliance brings together AMI’s instrumentation with Clinilabs’ core laboratory. Clinilabs’ core laboratory aggregates and processes electrocardiographic (ECG), polysomnographic (PSG), electroencephalographic (EEG), and electromyographic (EMG) data for clinical studies, offering pharmaceutical companies centralized services that standardize data obtained in multicenter trials. Centralized actigraphy has been offered jointly by Clinilabs and AMI since 2005.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
